Clearside Biomedical Inc expected to post a loss of 9 cents a share - Earnings Preview

Clearside Biomedical,

08/03/2024 20:45

* Clearside Biomedical Inc  CLSD.OQ   CLSD.O  is expected
to show
a rise in quarterly revenue when it reports  results on March 12
for the period ending December 31 2023
    * The Alpharetta Georgia-based  company is expected to
report a
1,243.4% increase in revenue to $4.433 million from $330
thousand a year ago, according to the mean estimate from 6
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Clearside Biomedical Inc
is
for a loss of 9 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Clearside
Biomedical Inc is $5.50​, above​ its last closing price
of $1.67. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.16       -0.15      -0.15     Met     3.2
 Jun. 30 2023  -0.14       -0.14      -0.15     Missed  -5.9
 Mar. 31 2023  -0.14       -0.14      -0.15     Missed  -7.1​
 Dec. 31 2022  -0.13       -0.13      -0.16     Missed  -27
 ​​Sep.        -0.05       -0.03      -0.13     Missed  -282.4
 30 2022                                                
 Jun. 30 2022  -0.13       -0.13      -0.13     Met     1.5​
 Mar. 31 2022  -0.08       -0.08      -0.13     Missed  -58.5
 Dec. 31 2021  0.12        0.16       0.31      Beat    95.8
 This summary was machine generated March 8 at 20:45 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)